This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2014
  • /
  • 06
  • /
  • Phase III trials of Movantik for OIC published in ...
Drug news

Phase III trials of Movantik for OIC published in NEJM-AstraZeneca

Read time: 1 mins
Last updated:20th Jun 2014
Published:20th Jun 2014
Source: Pharmawand

AstraZeneca has announced that the New England Journal of Medicine has published results of two pivotal Phase III studies � KODIAC-4 and KODIAC-5 of Movantik (naloxegol), an investigational treatment for Opioid-induced Constipation (OIC). Primary endpoint data from the KODIAC-4 and -5 studies showed that more OIC patients treated with naloxegol 25 mg had a consistent response of increased spontaneous bowel movements (SBMs) through 12 weeks of treatment compared to placebo [44% vs. 29% and 40% KODIAC-4 vs. 29% KODIAC-5)].

The 12.5 mg dose in KODIAC-5 did not show statistical significance for the primary endpoint. The 25 mg dose also demonstrated a higher response rate through 12 weeks of treatment compared to placebo in patients with laxative inadequate response, a secondary endpoint. Results for an additional secondary endpoint showed that patients taking naloxegol 25 mg in the KODIAC-4 and KODIAC-5 studies were likely to have a first post-dose spontaneous bowel movement 25-30 hours sooner than placebo. See: "Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain" William D. Chey et al. N Engl J Med 2014 v370 p2387-2396 June 19, 2014 DOI: 10.1056/NEJMoa1310246

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.